Trial intelligence / Profile preview

Retatrutide renal function study in overweight or obese adults with chronic kidney disease

2023-504583-42-00Phase 2Completed

Sponsor: Eli Lilly and Company
Start: May 2024
Modality: Peptides
Countries: 5

Overview

Phase 2, randomised, double-blind trial in chronic kidney disease (CKD), Overweight, obesity and 1 more comparing Retatrutide with Placebo comparator (2 arms). Started May 2024; status: completed.

Drugs

retatrutide

Conditions

chronic kidney disease (CKD)Overweightobesitytype 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on 2023-504583-42-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-504583-42-00.